TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $12.08 Consensus Price Target from Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been assigned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.79.

Several equities research analysts have commented on TLSI shares. Canaccord Genuity Group cut their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Roth Mkm started coverage on TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 price objective on the stock. Northland Securities initiated coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Finally, Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences during the 2nd quarter worth about $1,184,000. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter worth about $240,000. Duquesne Family Office LLC boosted its stake in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the period. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences in the third quarter valued at approximately $184,000. Finally, Walleye Capital LLC purchased a new stake in TriSalus Life Sciences during the 3rd quarter worth approximately $66,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock opened at $3.81 on Friday. The stock has a market capitalization of $116.18 million, a PE ratio of -1.53 and a beta of 0.56. The business has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $4.98. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.